Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

FDA Approves First Quadrivalent Flu Vaccine

FluMist Quadrivalent, a vaccine developed by AstraZeneca plc's (AZN: Quote) MedImmune unit, has been approved by the FDA for the prevention of seasonal influenza in people aged 2 years through 49 years.

FluMist Quadrivalent is the first influenza vaccine to contain four strains of the influenza virus - two influenza A strains and two influenza B strains. All other currently available licensed seasonal influenza vaccines, are trivalent, containing only three influenza virus strains namely, two strains of influenza A and one of influenza B.

Some of the approved trivalent flu vaccines are CSL Biotherapies' Afluria; Novartis' Agriflu; GlaxoSmithKline's Fluarix; ID Biomedical Corp.'s FluLaval; MedImmune's FluMist, and Sanofi Pasteur Inc.'s Fluzone and Fluzone High-Dose.

According to federal health officials, FluMist Quadrivalent increases the likelihood of adequate protection against circulating influenza B strains.

The newly approved FluMist Quadrivalent is administered as a spray into the nose, similar to the trivalent FluMist vaccine.

Influenza, commonly referred to as flu, is a contagious viral infection, associated with aches, pains, tiredness, sore throat and a runny nose. The symptoms may last from three to five days and can make a person quite ill for a few weeks.

Register
To receive FREE breaking news email alerts for AstraZeneca PLC and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Twitter Inc. has replaced its head of product Daniel Graf just six months after luring him over from Google, according to multiple reports. Graf, previously known for his work leading Google Maps will retain his vice president of product title and work on Twitter's geolocation features, the Wall Street... LinkedIn Corp., the world's largest online professional network, said Thursday after the markets closed that its third quarter loss widened slightly from last year, as higher costs and expenses more than offset a 45% increase in revenue. However, the company's quarterly earnings per share, excluding items, came in above analysts' expectations as did its quarterly revenue. Visa Inc., the world's largest payment card processor, said Wednesday that its fourth quarter profit fell 10% from last year, hurt mainly by a hefty litigation provision even as revenue increased 9%. However, the company's quarterly earnings per share, excluding items, came in above analysts' expectations as did its quarterly revenue.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.